Hetlioz

Hetlioz · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 1, 2027

~1.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (58)

Feb 21, 2041method-of-use (U-3003)US 11759446
Feb 21, 2041method-of-use (U-3003)US 11759446
Dec 11, 2040formulationUS 11202770
Dec 11, 2040method-of-use (U-3003)US 12447141
Aug 29, 2035method-of-use (U-3003)US 10179119
Aug 29, 2035method-of-use (U-3003)US 10179119
Aug 29, 2035method-of-use (U-3003)US 11266622
Aug 29, 2035method-of-use (U-3003)US 11266622
Jul 27, 2035method-of-use (U-3007)US 10376487
Jul 27, 2035method-of-use (U-3007)US 10376487
Feb 12, 2035compositionUS 10071977
Feb 12, 2035compositionUS 10071977
Feb 12, 2035compositionUS 10829465
Feb 12, 2035compositionUS 10829465
Feb 12, 2035compositionUS 11566011
Feb 12, 2035compositionUS 11566011
Feb 12, 2035compositionUS 11760740
Feb 12, 2035compositionUS 11760740
Feb 12, 2035compositionUS 12049457
Feb 12, 2035compositionUS 12049457
Oct 10, 2034method-of-use (U-3007)US 10610511
Oct 10, 2034method-of-use (U-2615)US 10610511
Oct 10, 2034method-of-use (U-3007)US 11141400
Oct 10, 2034method-of-use (U-3007)US 11141400
Oct 10, 2034method-of-use (U-3739)US 11786502
Oct 10, 2034method-of-use (U-3007)US 11786502
May 17, 2034method-of-use (U-3005)US 9730910
May 17, 2034method-of-use (U-3005)US 9730910
Apr 7, 2033method-of-use (U-3343)US 11918556
Apr 7, 2033method-of-use (U-3342)US 11918556
Jan 25, 2033method-of-use (U-3006)US 10149829
Jan 25, 2033method-of-use (U-3006)US 10149829
Jan 25, 2033method-of-use (U-2149)US 10449176
Jan 25, 2033method-of-use (U-3009)US 10610510
Jan 25, 2033method-of-use (U-2805)US 10610510
Jan 25, 2033method-of-use (U-2149)US 10945988
Jan 25, 2033method-of-use (U-3107)US 10980770
Jan 25, 2033method-of-use (U-3106)US 10980770
Jan 25, 2033method-of-use (U-3343)US 11285129
Jan 25, 2033method-of-use (U-3342)US 11285129
Jan 25, 2033method-of-use (U-3003)US 11633377
Jan 25, 2033method-of-use (U-3003)US 11633377
Jan 25, 2033method-of-use (U-3343)US 11826339
Jan 25, 2033method-of-use (U-3342)US 11826339
Jan 25, 2033method-of-use (U-3003)US 11833130
Jan 25, 2033method-of-use (U-3003)US 11833130
Jan 25, 2033method-of-use (U-3343)US 11850229
Jan 25, 2033method-of-use (U-3342)US 11850229
Jan 25, 2033method-of-use (U-3003)US 11918557
Jan 25, 2033method-of-use (U-3865)US 11918557
Jan 25, 2033method-of-use (U-3865)US 12201604
Jan 25, 2033method-of-use (U-3003)US 12201604
Jan 25, 2033method-of-use (U-1710)US 9060995
Jan 25, 2033method-of-use (U-3004)US 9539234
Jan 25, 2033method-of-use (U-3004)US 9539234
Jan 25, 2033method-of-use (U-1486)US 9549913
Jan 25, 2033method-of-use (U-2149)US 9855241
Jan 25, 2033method-of-use (U-2147)US RE46604

FDA exclusivities (2)

Dec 1, 2027ODE-330Orphan Drug (7y)1.4y
Dec 1, 2027ODE-329Orphan Drug (7y)1.4y

tasimelteon

all catalysts(0)

News(0)

comments(0)

Report a data issue

Patent cliff

patents (58)

FDA exclusivities (2)

Trials studying tasimelteon